OTHER INFORMATION
−Removed: During the three-month period ended October 1, 2023, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted , terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).
+Added: During the three-month period ended March 31, 2024, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted , terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).
Exhibit Number
−Removed: 3.1 Amended and Restated By-laws of Cognex Corporation, effective August 2, 2023 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, as filed with the SEC on August 3, 2023)
+Added: 10.1+ Letter Agreement dated January 3, 2024 between Cognex Corporation and Paul D.
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934*
12 unchanged sentences
** Furnished herewith
+Added: + Indicates management contract or compensatory plan or arrangement
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: October 31, 2023 COGNEX CORPORATION
+Added: May 2, 2024 COGNEX CORPORATION
/s/ Robert J.
1 unchanged sentence
(Principal Executive Officer)
−Removed: Senior Vice President of Finance and Chief Financial Officer
+Added: Vice President of Finance and Corporate Controller
(Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.